Impact of Age on Real-World Outcomes of Bispecific Antibodies in Patients with Relapsed Refractory DLBCL: CUBIC Consortium Analysis
Year: 2026
Type: article
Study design: Observational Study
Abstract: Older patients with diffuse large B-cell lymphoma (DLBCL) have limited treatment options. Bispecific antibodies (BsAbs) are a novel immunotherapy with less acute toxicity compared to conventional therapies. This is a real-world analysis conducted to understand the safety and efficacy of BsAbs in older compared to younger patients. Adult patients with relapsed/refractory DLBCL who received commercially available BsAbs as a single agent between June 2023 and October 2025 across 10 U.S. centers in the CUBIC consortium were included. Key efficacy outcomes included response rates and survival; safety outcomes included cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The analysis included 256 patients stratified by 3 age groups: <65 (71 patients), 65-74 (81 patients), ≥75 (104 patients). Median prior lines of therapy was 3, 80% were refractory to most recent therapy, and 40% would have been considered pivotal trial ineligible. At median follow-up of 9 months, the 12-month progression-free survival (PFS) was 30% and 12-month overall survival (OS) was 45%. Grade ≥3 CRS occurred in 5% patients; ICANS grade ≥3 occurred in 2% patients. There was no statistically significant difference in outcomes between the 3 age cohorts <65, 65-74, ≥75 with 12-month PFS 21%, 26%, 38%; 12-month OS 35%, 42%, 49%; grade ≥3 CRS 6%, 5%, 4%; and grade ≥3 ICANS 3%, 2%, 1% respectively. On multivariable analysis, ECOG ≥2 and elevated LDH were associated with inferior PFS and OS. Our analysis demonstrates that BsAbs maintain comparable efficacy and safety across all age groups, including patients ≥75 years.
Source: Blood Advances
Authors: Swetha Kambhampati Thiruvengadam, Jomel-Meeko Manzano, Sairah Ahmed, Allison M Bock, Narendranath Epperla, Yazeed Sawalha, Andrew P Jallouk, Shakthi Bhaskar, Lorenzo Falchi, Pallawi Torka, Matthew A Lunning, Jennifer L. Crombie, Reid W Merryman, Ajay Major, Gulrayz Ahmed, Mehdi Hamadani, Amy Ayers, Geoffrey Shouse, Christopher R Flowers, Alexey V Danilov, Lu Chen, Alex F. Herrera, Ayushi Chauhan
Institutions: City Of Hope National Medical Center, City of Hope, The University of Texas MD Anderson Cancer Center, Huntsman Cancer Institute, The Ohio State University, Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Dana-Farber Cancer Institute, University of Colorado Anschutz, Medical College of Wisconsin
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: bispecific antibodies, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, elderly patients, age as prognostic factor, progression-free survival, overall survival, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immunotherapy safety, ECOG performance status, lactate dehydrogenase
Open Access status: gold
Estimated APC paid: $3,800
OpenAlex ID: W7236195206
